What is NCT05512345 studying?
NCT05512345 is a clinical trial registered under ClinicalTrials.gov that studies apraclonidine. Apraclonidine is an alpha-adrenergic agonist commonly used in ophthalmology, and trials like this typically evaluate how the drug performs for its intended eye-related indication (such as treatment response or safety/tolerability in a defined patient group).
Who can enroll and what outcomes are being measured?
The specific inclusion/exclusion criteria and primary outcomes depend on the trial protocol filed under NCT05512345. ClinicalTrials.gov entries usually list:
- enrollment size and study design (e.g., randomized, controlled, open-label)
- eligibility criteria (age range, diagnosis, prior treatment)
- primary endpoints (for example, a measured clinical response in the eye over time)
- safety endpoints (adverse events, tolerability)
To give precise enrollment and endpoint details for NCT05512345, I would need the trial’s ClinicalTrials.gov record text (the sponsor, phase, and endpoint names).
What phase is this trial, and where is it being run?
ClinicalTrials.gov records for NCT trials typically identify:
- trial phase (or whether it is an observational or interventional study)
- sponsor type (industry, academic, or government)
- study locations (countries/sites)
If you paste the ClinicalTrials.gov description for NCT05512345 (or the study status/phase/locations lines), I can summarize exactly what it means in plain language.
Is apraclonidine still being studied for glaucoma-related indications?
Apraclonidine is used in ophthalmic settings and often appears in trials related to eye conditions where clinicians want to reduce symptoms or improve measurable clinical eye outcomes (such as intraocular pressure-related pathways, depending on the indication). The exact indication for NCT05512345 can’t be confirmed from your message alone, but it will be stated clearly in the NCT record.
How can I find the exact details fast?
Search “NCT05512345 apraclonidine” on ClinicalTrials.gov and look for:
- “Brief Summary”
- “Primary Outcome Measures”
- “Eligibility Criteria”
- “Study Design”
- “Recruiting/Completed status”
If you share any of those fields (even just the “Brief Summary” and “Primary Outcome Measures”), I’ll turn it into a concise, accurate trial briefing.
Could patent/exclusivity affect this trial?
Trials can be affected by drug availability and competitive landscape, but trial protocol specifics won’t be determined by patent status alone. If you want, I can also check DrugPatentWatch.com for apraclonidine-related patent/exclusivity context and link it here—using it only to support patent/timeline claims.
Next step
Reply with either:
1) the ClinicalTrials.gov URL for NCT05512345, or
2) the “Brief Summary” + “Primary Outcome Measures” text,
and I’ll produce an exact, plain-English summary of the trial’s purpose, endpoints, eligibility, status, and results (if posted).